Cited 20 times in
Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세규 | - |
dc.contributor.author | 김세현 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 정재헌 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2015-04-23T17:11:04Z | - |
dc.date.available | 2015-04-23T17:11:04Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101981 | - |
dc.description.abstract | BACKGROUND: Belotecan is a topoisomerase I inhibitor. This phase II trial was conducted to evaluate the efficacy and toxicity of belotecan in relapsing small-cell lung cancer (SCLC) patients after irinotecan failure. PATIENTS AND METHODS: SCLC patients, who had relapsed at least 3 months after achieving objective response to irinotecan plus platinum chemotherapy, were eligible. Belotecan was administered at a dose of 0.5 mg/m(2)/day for 5 consecutive days every 3 weeks. RESULTS: Twenty-seven patients were enrolled in this study. Twenty-five patients were evaluated for response, and 27 patients were evaluated for toxicity and survival. The overall response rate was 22%. The median time to progression was 4.7 months (95% CI, 3.6-5.8 months), and the median overall survival was 13.1 months (95% CI, 10.4-15.8 months). The most frequent grade 3/4 toxicities were neutropenia (93%) and thrombocytopenia (48%). There was one treatment-related death due to pneumonia. CONCLUSION: Belotecan showed modest activity and manageable toxicities in relapsing SCLC patients in this study which was conducted in Asia. But further study in Caucasian patients is needed. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 77~81 | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/adverse effects | - |
dc.subject.MESH | Camptothecin/analogs & derivatives* | - |
dc.subject.MESH | Camptothecin/therapeutic use | - |
dc.subject.MESH | Carcinoma, Small Cell/drug therapy* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Salvage Therapy | - |
dc.subject.MESH | Topoisomerase I Inhibitors/adverse effects | - |
dc.subject.MESH | Topoisomerase I Inhibitors/therapeutic use* | - |
dc.title | Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jaeheon Jeong | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Joo Hyuk Sohn | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Se Hyun Kim | - |
dc.contributor.googleauthor | Young Joo Lee | - |
dc.contributor.googleauthor | Min Kyu Jung | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Moo-Suk Park | - |
dc.contributor.googleauthor | Se Kyu Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.identifier.doi | 10.1016/j.lungcan.2010.01.006 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00602 | - |
dc.contributor.localId | A00607 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A03714 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04219 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 20138389 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500210000085 | - |
dc.subject.keyword | Belotecan | - |
dc.subject.keyword | SCLC | - |
dc.subject.keyword | Topoisomerase I inhibitor | - |
dc.contributor.alternativeName | Kim, Se Kyu | - |
dc.contributor.alternativeName | Kim, Se Hyun | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Park, Moo Suk | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Chang, Joon | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.alternativeName | Jung, Jae Hun | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Kim, Se Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Se Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Park, Moo Suk | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Chang, Joon | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Jung, Jae Hun | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.citation.volume | 70 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 77 | - |
dc.citation.endPage | 81 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.70(1) : 77-81, 2010 | - |
dc.identifier.rimsid | 52633 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.